Impel NeuroPharma nasal spray to treat migraine gets USFDA okay
New Delhi: Impel NeuroPharma Inc's nasal spray to treat migraine got approval from the U.S. health regulator on Friday, marking the company's entry into a crowded market of medicines for a disease that affects about 39 million Americans.
The drug, Trudhesa, can be self-administered to the bloodstream by being sprayed in the upper part of the nasal canal and is formulated using dihydroergotamine (DHE), an agent that works on the serotonin receptors linked to migraine.
Impel will price the treatment between $600 and $850 for a pack containing four doses and is aiming for more than $500 million in peak sales, Chief Executive Officer Adrian Adams told Reuters.
The Seattle-based company, which went public in April, plans to commercially launch Trudhesa in early October. Its rivals include Biohaven Pharmaceutical's Nurtec ODT and AbbVie Inc's Ubrelvy, both of which are orally administered.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.